Boundless Bio to Cut Jobs by One-Third as Part of Portfolio Prioritization

Dow Jones

May 24, 2025

By Roshan Fernandez

Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization.

The clinical-stage oncology company said it had 64 employees as of March 21, which would put the cuts at about 21 jobs. The company expects to incur about $1.2 million in one-time costs related to the job cuts, according to a filing with the Securities and Exchange Commission.

The San Diego company said the combination of efforts, which also include a streamlining of operations and short-term investments of $138.3 million, would extend its operating runway into the first half of 2028.

Boundless Bio said it is discontinuing a clinical trial, and prioritizing the novel combination of BBI-355 and BBI-825, along with its Kinesin program.

"We're concentrating our resources where we see the greatest potential to develop meaningful medicines," Chief Executive Zachary Hornby said.

Write to Roshan Fernandez at roshan.fernandez@wsj.com

(END) Dow Jones Newswires

May 23, 2025 16:44 ET (20:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537152219"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537152219\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537152219?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-24 04:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537152219","market":"other","top_or_hot":-1,"title":"Boundless Bio to Cut Jobs by One-Third as Part of Portfolio Prioritization","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization. \n</p>\n<p>\n  The clinical-stage oncology company said it had 64 employees as of March 21, which would put the cuts at about 21 jobs. The company expects to incur about $1.2 million in one-time costs related to the job cuts, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  The San Diego company said the combination of efforts, which also include a streamlining of operations and short-term investments of $138.3 million, would extend its operating runway into the first half of 2028. \n</p>\n<p>\n  Boundless Bio said it is discontinuing a clinical trial, and prioritizing the novel combination of BBI-355 and BBI-825, along with its Kinesin program. \n</p>\n<p>\n  \"We're concentrating our resources where we see the greatest potential to develop meaningful medicines,\" Chief Executive Zachary Hornby said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:44 ET (20:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boundless Bio to Cut Jobs by One-Third as Part of Portfolio Prioritization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoundless Bio to Cut Jobs by One-Third as Part of Portfolio Prioritization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-24 04:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Roshan Fernandez \n</p>\n<pre>\n \n</pre>\n<p>\n  Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization. \n</p>\n<p>\n  The clinical-stage oncology company said it had 64 employees as of March 21, which would put the cuts at about 21 jobs. The company expects to incur about $1.2 million in one-time costs related to the job cuts, according to a filing with the Securities and Exchange Commission. \n</p>\n<p>\n  The San Diego company said the combination of efforts, which also include a streamlining of operations and short-term investments of $138.3 million, would extend its operating runway into the first half of 2028. \n</p>\n<p>\n  Boundless Bio said it is discontinuing a clinical trial, and prioritizing the novel combination of BBI-355 and BBI-825, along with its Kinesin program. \n</p>\n<p>\n  \"We're concentrating our resources where we see the greatest potential to develop meaningful medicines,\" Chief Executive Zachary Hornby said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 23, 2025 16:44 ET (20:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOLD","symbol_name":"Boundless Bio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537152219","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537152219","pubTimestamp":1748033040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization.The clinical-stage oncology company said it had 64 employees as of March 21, which would put the cuts at about 21 jobs. The company expects to incur about $1.2 million in one-time costs related to the job cuts, according to a filing with the Securities and Exchange Commission.The San Diego company said the combination of efforts, which also include a streamlining of operations and short-term investments of $138.3 million, would extend its operating runway into the first half of 2028.Boundless Bio said it is discontinuing a clinical trial, and prioritizing the novel combination of BBI-355 and BBI-825, along with its Kinesin program.\"We're concentrating our resources where we see the greatest potential to develop meaningful medicines,\" Chief Executive Zachary Hornby said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOLD":"Boundless Bio, Inc.","BK4139":"生物科技"},"translate_title":"作为投资组合优先顺序的一部分，Boundless Bio将裁员三分之一","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOLD":1},"content_text":"By Roshan Fernandez \n\n\n \n\n\n  Boundless Bio said it would reduce its workforce by about one-third as part of a portfolio prioritization. \n\n\n  The clinical-stage oncology company said it had 64 employees as of March 21, which would put the cuts at about 21 jobs. The company expects to incur about $1.2 million in one-time costs related to the job cuts, according to a filing with the Securities and Exchange Commission. \n\n\n  The San Diego company said the combination of efforts, which also include a streamlining of operations and short-term investments of $138.3 million, would extend its operating runway into the first half of 2028. \n\n\n  Boundless Bio said it is discontinuing a clinical trial, and prioritizing the novel combination of BBI-355 and BBI-825, along with its Kinesin program. \n\n\n  \"We're concentrating our resources where we see the greatest potential to develop meaningful medicines,\" Chief Executive Zachary Hornby said. \n\n\n \n\n\n  Write to Roshan Fernandez at roshan.fernandez@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 16:44 ET (20:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}